AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology January 21, 2025
FDA Clears 225Ac-Satoreotide Ph 1/2 Clinical Study in Patients with SCLC or Merkel Cell Carcinoma January 21, 2025
FDA Approves Lumakras® (Sotorasib) + Vectibix® (Panitumumab) For Chemorefractory KRAS G12C-Mutated Metastatic CRC January 21, 2025
Simnova and Orna Expand Strategic Partnership to Include BCMA-Targeted RNA Therapeutics January 21, 2025
European Clinical Trial Sites opened and Initial Dosing of Cohort 4 completed for PAS-004 Ph 1 trial January 21, 2025
Positive Topline Results for TIVDAK in the China Subpopulation of the Global Ph 3 innovaTV 301 Trial in Patients with Recurrent/Metastatic Cervical Cancer Announced January 21, 2025
NDA initiated with US FDA for TAR-200 for patients with BCG-unresponsive high-risk NMIBC January 21, 2025
Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma January 21, 2025
ArsenalBio and BMS Achieve Milestone for AB-4000 Series to Advance Next-Gen T Cell Therapies for Solid Tumors January 21, 2025
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Precision Cell Therapies Using Proprietary Tmod Technology Platform January 21, 2025
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma January 21, 2025
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs January 21, 2025
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage CTCL January 21, 2025
BLA submission of ANKTIVA planned in 2025 for 2/3L treatment of patients with NSCLC, who are progressing on checkpoint inhibitors January 21, 2025
European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer January 21, 2025
Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR+ve, HER2-neg breast cancer January 21, 2025
